Insight Molecular Diagnostics (IMDX) Other Gross PP&E Adjustments (2020 - 2025)
Insight Molecular Diagnostics (IMDX) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with -$15.0 million as the latest value for Q4 2025.
- Quarterly Other Gross PP&E Adjustments fell 54.93% to -$15.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.0 million through Dec 2025, down 54.93% year-over-year, with the annual reading at -$15.0 million for FY2025, 54.93% down from the prior year.
- Other Gross PP&E Adjustments hit -$15.0 million in Q4 2025 for Insight Molecular Diagnostics, down from -$12.9 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $4.7 million in Q2 2021 to a low of -$15.7 million in Q3 2022.
- Historically, Other Gross PP&E Adjustments has averaged -$8.4 million across 5 years, with a median of -$10.8 million in 2023.
- Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 441.68% in 2021 and later tumbled 881.41% in 2023.
- Year by year, Other Gross PP&E Adjustments stood at -$4.5 million in 2021, then crashed by 203.02% to -$13.7 million in 2022, then surged by 32.45% to -$9.3 million in 2023, then dropped by 4.34% to -$9.7 million in 2024, then plummeted by 54.93% to -$15.0 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for IMDX at -$15.0 million in Q4 2025, -$12.9 million in Q3 2025, and -$12.6 million in Q2 2025.